

Fund Summary

OptiMix Australian Shares

OneAnswer Frontier Personal Super

30 September 2025

Fund details

Investment manager	OptiMix
Fund code	MMF1781AU
Asset type	Equity Australia Large Blend
Region	Australia
Fund size	\$27.71 million as at 30 Sep 2025
Commencement date	15 Nov 2010
Distributions	Retained

Investment objective

The fund aims to achieve returns (before fees, charges and taxes) that exceed the S&P/ASX 300 Accumulation Index, over periods of five years or more.

Investment strategy

The fund invests predominantly in a diversified portfolio of Australian shares through a mix of managers. The fund is actively managed in accordance with the OptiMix Multi-manager investment process.

Fund performance

As at 30 Sep 2025

	1 mth	3 mth	1 yr	3 yr	5 yr	7 yr	10 yr
	%	%	%	% pa	% pa	% pa	% pa
Total Return †	-0.76	4.83	8.74	12.72	11.41	7.67	8.49
Benchmark ‡	-0.65	4.99	10.76	15.03	12.88	9.25	10.11
Excess Return	-0.11	-0.16	-2.02	-2.31	-1.47	-1.58	-1.62

Calender year

returns	YTD	2024	2023	2022	2021
Total Return †	9.23	10.58	11.27	-0.77	15.11
Benchmark ‡	11.66	11.39	12.13	-1.77	17.54
Excess Return	-2.43	-0.81	-0.86	1.00	-2.43

Top 10 holdings

Security	% of fund
Bhp Group Limited	7.89%
Commonwealth Bank Of Australia	5.96%
National Australia Bank Limite	4.17%
Anz Group Holdings Limited	3.43%
Csl Limited	3.21%
Westpac Banking Corporation	2.60%
Macquarie Group Limited	2.25%
Telstra Group Limited	2.23%
Resmed Inc.	1.72%
Wesfarmers Limited	1.67%
Total Top 10	35.13%

Minimum time horizon

5 years

Standard Risk Measure*

The Standard Risk Measure (SRM) is based on industry guidance to allow investors to compare funds that are expected to deliver a similar number of negative annual returns over any 20 year period. The SRM for this fund is shown below:



Asset allocation



* For further information on Standard Risk Measures and the calculation methodology used, go to onepath.com.au/personal/performance/product-updates.aspx

† Returns quoted use the unit price which is calculated using the net asset values for the relevant month end. The prices shown may differ from the actual unit price if an investor is applying for or redeeming an investment. Actual unit prices will be confirmed following any transaction on an investor's investment. Please note that all returns are after the deduction of management fees and expenses and assumes all distributions are re-invested. Where applicable, management fees have been deducted at the highest entry fee option rate. No allowance has been made for entry or exit fees.

‡ Benchmark (S&P/ASX 300 TR) returns should be used for indicative purposes only. These returns may not be a true indication of this Fund's performance against its investment objective.

Fund Summary

OptiMix Australian Shares

OneAnswer Frontier Personal Super

30 September 2025

Market and portfolio review

Australian Equities rose in the September quarter, and were buoyed by the RBA rate cut in August and the strong returns generated by the resources sector. Acorn outperformed during the period due to positive stock selection in the materials, information technology, and health care sectors, and from being overweight materials and information technology. OC Micro Caps underperformed its own benchmark but outperformed the ASX 300 Accumulation index. Outperformance versus the ASX 300 was due to being overweight industrials and information technology and from positive stock selection in these sectors. OC Small Caps underperformed its own benchmark but outperformed the ASX 300 Accumulation index. Outperformance versus the ASX 300 was due to being overweight information technology and industrials and from positive stock selection in these sectors. Quest outperformed mostly due to positive stock selection in financials. Having no exposure to Commonwealth Bank of Australia was by far the largest single contributor to the managers outperformance. Northcape underperformed due to negative stock selection in materials and financials and from being overweight healthcare. Antares underperformed due to being overweight health care and underweight materials and from negative stock selection in these sectors. Selector underperformed mostly due to negative stock selection in the materials sector. Alphinity underperformed due to being underweight materials and from negative stock selection in this sector and in the energy sector.

Future investment strategy

The Trust generally gains its investment exposure by investing in a well diversified portfolio of Australian share investment managers. The Trust's investments generally provide exposure to stocks within the S&P/ASX 300 Accumulation Index. The Trust is authorised to utilise approved derivative instruments subject to the specific restriction that derivative instruments cannot be used to gear the portfolio exposure.

OnePath Funds Management Limited (ABN 21 003 002 800 AFSL 23 8342) and OnePath Custodians Pty Limited (ABN 12 008 508 496 AFSL 238346 RSE L0000673) are the issuers of this material. Except as described in the relevant Product Disclosure Statement (PDS), the issuers do not stand behind or guarantee the capital or performance of your investment. Your investment is subject to investment risk, including possible repayment delays and loss of income and principal invested.

This information is current as at 30 Sep 2025 with the commentary current for the most recent quarter end (eg. March, June, Sept or Dec) however in some cases may be applicable for the preceding month or quarter end. Updated information will be available free of charge by contact Client Services on 133 665. The information is of a general nature and does not take into account your personal needs, financial circumstances or objectives. Before acting on this information, you should consider the appropriateness of the information, having regard to your needs, financial circumstances and objectives. Past performance is not indicative of future performance. The future value of investments may rise and fall with changes in the market. You should read the relevant PDS available at onepath.com.au and consider whether that particular product is right for you before making a decision to acquire or continue to hold the product.

